AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC).

UroGen Pharma (NASDAQ:URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Though the connection seems unusual, this news could change the lives of more than 700,000 Americans living with this disease ...

If you have bladder cancer, there are several treatment options. Your doctor will help you decide which one is best for you. Choosing the best treatment depends on a number of things ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

This new immunotherapy is particularly effective in several types of solid tumors, but it will take time to confirm its ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

ImmunityBio is seeking an urgent meeting with U.S. health regulators after its bladder-cancer treatment application was rejected. The immunotherapy company said Monday that it received a ...